C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter D—Drugs for Human UsePart 314—Applications for Fda Approval to Market A New DrugSubpart H—Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses

21 C.F.R. § 314.520 (2026)

Approval with restrictions to assure safe use

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 cited 2009–2023 19citing cases
At a glance

Courts have cited this section in 19 opinions since 2009, 5 of them in the last five years.

(a) If FDA concludes that a drug product shown to be effective can be safely used only if distribution or use is restricted, FDA will require such postmarketing restrictions as are needed to assure safe use of the drug product, such as:

(1) Distribution restricted to certain facilities or physicians with special training or experience; or

(2) Distribution conditioned on the performance of specified medical procedures.

(b) The limitations imposed will be commensurate with the specific safety concerns presented by the drug product.

The 19 cases that cite 21 C.F.R. § 314.520 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENPlanned Parenthood Se. Ohio Region v. DeWine, 696 F.3d 490 (6th Cir. 2012).
cites § 314.520 2×cited by 93 cases
Where it cites § 314.520
“at 188 (FDA Approval Letter at 2); 21 C.F.R. § 314.520 . Following FDA approval, additional clinical trials led to the development of new protocols for administering the drugs, one of which called for “200 mg of mifepristone administered orally followed one to three days later…”
The case’s holding
A district court may certify a partial grant of summary judgment for immediate appeal under Rule 54(b) when the claims involve distinct constitutional rights and injuries.
Later courts cite it for
“proper certification under rule 54(b) is a two-step process.” · 3 citing courts
2
GREENCordray v. Planned Parenthood Cincinnati Region, 2009-Ohio-2972, 911 N.E.2d 871.
cites § 314.520 8×cited by 6 cases
Where it cites § 314.520
“” {¶ 6} Further, in its drug approval letter, the FDA, pursuant to 21 C.F.R. 314.520, imposed an additional restriction that mifepristone “be provided by or under the supervision of a physician who meets the following qualifications: {¶ 7} “[1.”
Later courts cite it for
“pursuant to r.c. 2919.123, a physician may provide mifepristone for the purpose of inducing an abortion only through the patient's 49th day of pregnancy and only by using the dosage indications and treatment protocols expressly approved by the fda in the drug's final printed labeling as incorporated by the drug approval letter.” · 2 citing courts
3
REDAll. Hippocratic Med. v. FDA, 78 F.4th 210 (5th Cir. 2023).
cites § 314.520 2×cited by 24 cases
Reversed by FDA v. Alliance for Hippocratic Medicine (2024): the U.S. Supreme Court's own opinion in this case.
Where it cites § 314.520
“” 21 C.F.R. § 314.520 (emphasis omitted). Mifepristone was approved under § 314.”
The case’s holding
An associational standing claim requires demonstrating a substantial risk of future injury to members through predictable and consistent agency policies.
Later courts cite it for
“all of this violates the comstock act.” · 3 citing courts
4
cites § 314.520 3×cited by 9 cases
Where it cites § 314.520
“Specifically, the Code of Federal Regulations (CFR) provides for accelerated approval of certain drugs that are shown to be effective but "can be safely used only if distribution or use is restricted"; 3.”
5
GREENTummino v. Hamburg, 936 F. Supp. 2d 162 (E.D.N.Y. 2013).
cites § 314.520 4×cited by 7 cases
Where it cites § 314.520
“Indeed, rather than rely on § 355(d), it argued that FDA regulations, specifically 21 C.F.R. § 314.520 , expressly authorized it to restrict distribution of Plan B to select pharmacies and health clinics.”
6
GREENJazz Pharm., Inc. v. Amneal Pharm., LLC, 895 F.3d 1347 (Fed. Cir. 2018).
cites § 314.520 1×cited by 22 cases
Where it cites § 314.520
“11055; see 21 C.F.R. § 314.520 . During the regulatory review process for Xyrem ® , the FDA scheduled an advisory committee meeting for June 6, 2001.”
Later courts cite it for
“whether a reference qualifies as a 'printed publication' . . . is a legal conclusion based on underlying factual findings.” · 4 citing courts
7
REDPlanned Parenthood of Arizona v. William Humble, 753 F.3d 905 (9th Cir. 2014).
cites § 314.520 1×cited by 52 cases
Abrogated by Dobbs v. Jackson Women's Health Organization on other grounds: 2 citing opinions limit it to other grounds and 1 says abrogated outright.
Where it cites § 314.520
“See 21 C.F.R. § 314.520 . These restrictions require the manufacturer to distribute mifepristone only to doctors who sign an agreement “stating that he or she possesses the necessary qualifications and will adhere to the other requirements.”
The case’s holding
The undue burden test requires weighing the severity of a regulation's burden against the strength of the state's justification within the specific context of the law.
Later courts cite it for
“to weigh the extent of the burden against the strength of the state's justification in the context of each individual statute or regulation.” · 7 citing courts
cites § 314.520 1×cited by 22 cases
Where it cites § 314.520
“See 21 C.F.R. § 314.520 . Although the FDA required mifepristone's sponsor to distribute the drug only under conditions where it would be provided by or under the supervision of a physician who was able to meet certain criteria, the FDA did not go so far as to require that…”
The case’s holding
A statute requiring physicians to prescribe abortion-inducing drugs strictly according to FDA-approved labels prohibits the off-label use of misoprostol for abortions and methotrexate for ectopic pregnancies.
Later courts cite it for
“is so completely at odds with the standard that governs the practice of medicine that it can serve no purpose other than to prevent women from obtaining abortions and to punish and discriminate against those who do.” · 4 citing courts
9
GREENChristison v. Biogen Idec Inc., 199 F. Supp. 3d 1315 (D. Utah 2016).
cites § 314.520 1×cited by 5 cases
Where it cites § 314.520
“, under 21 CFR 314.520 and 601.42 “Approval with restrictions to assure safe use” or under 505-l(f)(3) of the *1324 Federal Food, Drug, and Cosmetic Act (FDCA) “Risk Evaluation and Mitigation Strategies” Elements to assure safe use).”
10
GREENIn re Actiq Sales & Mktg. Practices Litig., 307 F.R.D. 150 (E.D. Pa. 2015).
cites § 314.520 1×cited by 6 cases
Where it cites § 314.520
“For a small class of prescription drugs, the FDA will grant approval under the distribution regulations of 21 C.F.R. § 314.520 (“Subpart H”), which is reserved for drug products that are effective but carry significant safety risks.”
11
cites § 314.520 1×cited by 14 cases
Where it cites § 314.520
“The FDA approved mifepristone (brand name Mifeprex) under the rubric of 21 C.F.R., Section 314.520, also referred to as "Subpart H", which is the only FDA approval process that allows for postmarketing restrictions, Specifically, the Code of Federal Regulations (CFR) provides…”
12
NO FLAGOkla. Coal. for Reprod. Just. v. Cline, 441 P.3d 1145 (Okla. 2019).
cites § 314.520 1×cited by 7 cases
Where it cites § 314.520
“The FDA approved mifepristone (brand name Mifeprex) under the rubric of 21 C.F.R., Section 314.520, also referred to as "Subpart H", which is the only FDA approval process that allows for postmarketing restrictions.”
cites § 314.520 3×cited by 0 cases
Where it cites § 314.520
“The FDA approved mifepristone (brand name Mifeprex) under the rubric of 21 C.F.R., Section 314.520, also referred to as "Subpart H", which is the only FDA approval process that allows for postmarketing restrictions.”
The case’s holding
A statute incorporating the current FDA final printed labeling for specified abortion drugs, without adopting future FDA changes, is not an unconstitutional delegation and may be a permissible special law.
Later courts cite it for
“while h.b. 2684 does not prohibit all medication abortions, it nonetheless binds oklahoma physicians and their patients to the fda's final printed labeling, regardless of whether evidence and the judgment of the medical community indicate it is not the best method for providing medication abortion.” · 2 citing courts
14
GREENAvadel CNS Pharm., LLC v. Becerra, 638 F. Supp. 3d 23 (D.D.C. 2022).
cites § 314.520 1×cited by 0 cases
Where it cites § 314.520
“§ 355-1 (a); 21 C.F.R. § 314.520 (2022). The Jazz REMS sets up a system of drug distribution through a single, central pharmacy and central computer database.”
15
NO FLAGAll. Hippocratic Med. v. FDA, No. 23-10362, 2023 WL 2913725 (5th Cir. Apr. 12, 2023).
cites § 314.520 1×cited by 0 cases
Where it cites § 314.520
“” 21 C.F.R. § 314.520 . As noted in the previous section, today we call such post-approval restrictions “REMS.”
16
NO FLAGGomperts v. Azar, No. 1:19-cv-00345 (D. Idaho July 13, 2020).
cites § 314.520 1×cited by 0 casesunknown
Where it cites § 314.520
“21 C.F.R. § 314.520 . For example, these restrictions mandate that Mifeprex be dispensed only in certain healthcare settings by a certified healthcare provider who can accurately assess the duration of a pregnancy, diagnose an ectopic pregnancy (for which Mifeprex is not…”
17
NO FLAGWhole Woman's Health All. v. United States Food & Drug Admin., No. 3:23-cv-00019 (W.D. Va. Aug. 21, 2023).
cites § 314.520 1×cited by 0 casesunknown
Where it cites § 314.520
“The imposed conditions in 2000 on the prescription of mifepristone required: (1) in- person dispensing of mifepristone only in a clinic, medical office, or hospital by or under the supervision of a certified provider, who could only be a physician, (2) a certification by…”
18
NEUTRALState of Washington v. United States Food & Drug Admin., 668 F. Supp. 3d 1125 (E.D. Wash. 2023).
cites § 314.520 1×cited by 0 casesunknown
Where it cites § 314.520
“58,942 , 58,958 (December 11, 1992) 9 (codified at 21 C.FR. § 314.520). In September 2000, FDA approved 10 mifepristone1 under Subpart H, concluding that mifepristone is safe and effective 11 for medical termination of intrauterine pregnancy through 49 days’ gestation when 12…”
Later courts cite it for
“whether the 7 briefing supplements the efforts of counsel, and draws the court's attention to law that 8 escaped consideration.” · 2 citing courts
19
REDPlanned Parenthood of Arizona v. William Humble, No. 14-15624 (9th Cir. June 3, 2014).
cites § 314.520 1×cited by 0 cases
Where it cites § 314.520
“See 21 C.F.R. § 314.520 . These restrictions require the manufacturer to distribute mifepristone only to doctors who sign an agreement “stating that he or she possesses the necessary qualifications and will adhere to the other requirements.”

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
200920162023

One bar per year. Tallest: 4 cases in 2023. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
Okla.55th Cir.29th Cir.26th Cir.1Fed. Cir.1D.D.C.1D. Idaho1E.D.N.Y1

The 8 courts with the most citing cases, of 13 courts in all.

By subsection

Courts have not cited this section by subsection, so its cases are not split up here. The Leading cases tab lists the cases that cite it most heavily.

Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com